COL7A1 and recessive dystrophic epidermolysis bullosa: Therefore, to further develop our gene replacement therapy for RDEB treatment, employment of a human promoter sequence to control COL7A1 expression may help to minimize the risk of immunogenic and/or oncogenic events, and avoid any other unexpected effects from a CMV promoter.